Gill Capital Partners’s Medifast MED Stock Holding History

Gill Capital Partners’s Portfolio MED Stock Details MED Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.15K	Hold	108	–	–	﹤0.01%	609
2026 Q1	$1.1K	Buy	+108	New	+$1.16K	﹤0.01%	592

Other funds holding MED

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

SCP

Steamboat Capital Partners Rye, New York $468M AUM 80.81% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Charles Schwab San Francisco, California $751B AUM 38.74% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Gill Capital Partners's MED Position: Q2 2026 in Review

Gill Capital Partners held its Medifast (MED) position steady in Q2 2026 at 108 shares worth $1.15K. The position accounts for ﹤0.01% of the portfolio, ranked #609.

Gill Capital Partners first reported a position in MED in Q1 2026 and has held it in 2 quarters since. 113 funds tracked by Wall St. Rank hold MED as of Q2 2026.

Gill Capital Partners held 108 shares of Medifast worth $1.15K as of Q2 2026.
Gill Capital Partners left its Medifast share count unchanged in Q2 2026.
Medifast made up ﹤0.01% of Gill Capital Partners's portfolio in Q2 2026, its #609 holding.
Gill Capital Partners first reported a position in Medifast in Q1 2026 and has held it in 2 quarters since.
113 funds tracked by Wall St. Rank held Medifast as of Q2 2026.

Based on Gill Capital Partners's 13F filing for Q2 2026, filed 20 Aug 2026.